Research News and Research

RSS

Accuri Cytometers, eBioscience announce worldwide co-marketing agreement

Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement.

10 May 2010

Achillion reports lower net loss of $5.6M for first-quarter 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.

10 May 2010

FASEB scientists call for increased funding for federal science agencies

Scientists from across the country came to Washington on May 5th to advocate for increased funding for federal science agencies as part of the Federation of American Societies for Experimental Biology's (FASEB) annual Capitol Hill Day.

10 May 2010

Medical options to help prostate cancer patients make informed treatment decisions

While the dreaded words "You have prostate cancer" often leave patients confused, the impact of the diagnosis can extend to the entire family, especially wives, says a top expert.

10 May 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010.

10 May 2010

American Oriental Bioengineering first-quarter revenue increases 16.7% to $53.7 million

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the first quarter ended March 31, 2010.

10 May 2010

Repros Therapeutics net loss decreases to $1.1M for first-quarter 2010

Repros Therapeutics today announced financial results for the first quarter ended March 31, 2010.

10 May 2010

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

A team of University of California, San Diego School of Medicine researchers has discovered that common intestinal bacteria appear to promote tumor growths in genetically susceptible mice, but that tumorigenesis can be suppressed if the mice are exposed to an inhibiting protein enzyme.

10 May 2010

Drug study results, interpretation favour wishes of sponsor pharmaceutical companies

Drug studies financed by pharmaceutical companies frequently show positive results in favour of the sponsor. In the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107(16): 279-85), a research group headed by the Chairman of the Drug Commission of the German Medical Association, Prof. Wolf-Dieter Ludwig, describes the influence of sponsoring on the results, protocol and quality of drugs studies.

10 May 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents

10 May 2010

More genetic sites associated with increase in breast cancer risk discovered

Scientists have found five new regions of the genome that increase a woman's risk of developing breast cancer by between six and 16 per cent, according to a study in Nature Genetics today (Sunday)1.

10 May 2010

CE 3D US creates spatial view for hemodynamic and morphologic evaluation of focal liver tumors

Recently, contrast-enhanced (CE) ultrasound (US) appeared as an important modality to show the vascularity in the areas of interest, and has been used widely in clinical diagnosis of liver lesions. Three dimensional ultrasonography (3D US) allows three orthogonal planes to spatially demonstrate the features of subjects, which has been frequently used in fetal US.

10 May 2010

Majority of Americans concerned about skin cancer but still like tans

When it comes to tanning, dermatologists have long suspected that most people need an attitude adjustment. Now, results of a new survey by the American Academy of Dermatology (Academy) confirmed that the majority of people still idolize the bronzed look of a tan despite wanting to protect themselves from skin cancer.

10 May 2010

UT Southwestern offers advanced lung-cancer patients free screenings of tumors for genetic mutations

UT Southwestern Medical Center is the only site in North Texas participating in a national study that offers advanced lung-cancer patients free screenings of their tumors for genetic mutations, some of which might be targets for treatment with existing or experimental therapies.

10 May 2010

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease. The study aims to validate non-invasive approaches to monitor the progression and treatment of Duchenne, and holds potential to facilitate the development of promising new therapies for people with the disease.

10 May 2010

UT Southwestern researchers uncover core function of gene involved in Fragile X syndrome

Researchers at UT Southwestern Medical Center have discovered how the genetic mutation that causes Fragile X syndrome, the most common form of inherited mental retardation, interferes with the "pruning" of nerve connections in the brain. Their findings appear in the April 29 issue of Neuron.

10 May 2010

NIH awards UF scientists $7.5M for study of MRI technology in evaluating children with DMD

Duchenne muscular dystrophy research at the University of Florida got a major boost with the award of $7.5 million in National Institutes of Health funding to study the use of magnetic resonance imaging in determining the natural progression of the disease.

10 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

BD Biosciences introduces new Influx Cell Sorting System

BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the launch of the new BD Influx™ Cell Sorting System that researchers can configure with up to seven lasers to support two-way, four-way and six-way sorting, giving them flexibility to meet specific application or environmental requirements.

From BD (Becton, Dickinson and Company) 10 May 2010

Parents, young adult children eagerly await health insurance expansion

The provision of the new health law that allows young adults to stay on their parents' insurance plan is in the news.

10 May 2010

Research News and Research

Accuri Cytometers, eBioscience announce worldwide co-marketing agreement

Achillion reports lower net loss of $5.6M for first-quarter 2010

FASEB scientists call for increased funding for federal science agencies

Medical options to help prostate cancer patients make informed treatment decisions

Lexicon Pharmaceuticals first-quarter revenues down 61%

American Oriental Bioengineering first-quarter revenue increases 16.7% to $53.7 million

Repros Therapeutics net loss decreases to $1.1M for first-quarter 2010

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

Drug study results, interpretation favour wishes of sponsor pharmaceutical companies

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

More genetic sites associated with increase in breast cancer risk discovered

CE 3D US creates spatial view for hemodynamic and morphologic evaluation of focal liver tumors

Majority of Americans concerned about skin cancer but still like tans

UT Southwestern offers advanced lung-cancer patients free screenings of tumors for genetic mutations

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

UT Southwestern researchers uncover core function of gene involved in Fragile X syndrome

NIH awards UF scientists $7.5M for study of MRI technology in evaluating children with DMD

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

BD Biosciences introduces new Influx Cell Sorting System

Parents, young adult children eagerly await health insurance expansion

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News